Polydocanol: Clinical Effects and Safety on Great Saphenous Vein (GSV) Insufficiency

Abstract

This study was designed to evaluate the clinical effect and safety of polydocanol injection on
the treatment of varicose great saphenous vein (GSV) and to analyze the effects on inflammatory markers
(IL-10); 86 patients with varicose saphenous veins of lower extremities were selected and divided into two
groups. The control group was treated with conventional surgery, while the study group was treated with
ultrasound-guided polydocanol injection. The p value 5% was considered statistically significant (P <
0.05). Compared with the control group, the study group had shorter duration of operation and hospitalization, lower intraoperative blood loss and complications, and higher satisfaction rate. There was no significant difference in PT, APTT and TT levels 7 days after operation between the two groups, but the FIB
and PAI-I levels were lower than the control group, and the t-PA levels were higher than the control
group. There was no significant difference in TNF-α level between the two groups 1 month after surgery,
but TNF-α A level in the study group 6 months after surgery was lower than that in the control group, IL6 level in the study group was lower than that in the control group, and IL-10 level was higher than that in
the control group 1 and 6 months after surgery. There was no significant difference in VCSS level between
the two groups before and 1 month after surgery, but VCSS level of the study group 6 months after
surgery was lower than that of the control group. In the treatment of varicose saphenous vein of lower extremity, the effect of polydocanol injection is ideal, which can improve the indicators of patients, reduce
the severity of the disease, improve the clinical effect, and is worthy of clinical application.